Risks of Using Aclasta Drug: Kidney Failure

Aclasta is used in patients who are suffering from osteoporosis, in order to reduce the incidence of fracture. Warning news focused on using Aclasta drug as it may trigger nephrosis in Kidney Failure patients, as per the Saudi Food and Drug Authority (SFDA).
The U.S. Food and Drug Administration (FDA) suggest that concentration test of serum creatinine should be taken before using Aclasta. FDA also supplemented some reports focusing on renal damages during clinic trails. After the Aclasta instruction has been updated, there were 11 deaths resulting from acute Kidney Failure after being injected Aclasta along with 9 cases needed dialysis.
Several indentified factors in Aclasta instruction increase the risks of renal toxicity. Risk factors which relate to the occurrence of Kidney Failure including:
1. Underlying renal damages in moderate or severe degree
2. Taking renal toxicity drugs together with Aclasta
3.Dehydration occurs before or after taking diuretic along with Aclasta
Among all those conditions, patients with underlying renal damages have increasing risks to develop to Kidney Failure over age. Aclasta is forbidden among people whose Ccr is lower than 35mL/min and those who are suffering from acute Kidney Failure. Patients-screening is necessary before doctors prescribing the drug, so as to find out at-risk patients. Monitoring the renal function for patients who take Aclasta is also needed.
Tips for both patients with Kidney Failure along with medical professionals:
1. It is forbidden that use Aclasta in patients with Ccr less than 35mL/min, and those who are suffering from acute Kidney Failure
2. Before prescribe the Aclasta for patients, patient-screening is still needed, to find out patients with potential acute or chronic Renal Failure and the elderly as well as patients with dehydration. Those with potential renal damages have the highest risk developing to Kidney Failure. Those patients all above should better take Aclasta with caution.
3. Patients with potential renal diseases caused by fever and septicaemia etc., those with dehydration have a high risk of suffering from Kidney Failure. Risks in patients with potential renal damages increases over age.
4. Ccr should be calculated before prescription. To at-risk patients, intermittent monitoring should be taken after Aclasta has been given. Ccr should base on the actual weight by using Cockcroft-Gault formula.